Table 4 (%) Antiviral activity of cyanobacterial EPS against different viruses using plaque assay
Virus | Concentration (µg/mL) | Treatment | Neutralization | Blocking |
|---|---|---|---|---|
HSV-1 | 5 | 76.9 ± 0.14 | 88 ± 1.4 | 44.7 ± 0.88 |
10 | 86.5 ± 0.7 | 93.5 ± 2.1 | 54.5 ± 1.1 | |
20 | 91.5 ± 1.83 | 99 ± 1.3 | 77.2 ± 1.3 | |
EC50 (µg/mL) | 0.8424 | 1.088 | 6.477 | |
SI (IC50/EC50) | 179.72 | 140.185 | 23.65 | |
HSV-2 | 5 | 54.79 ± 1.7 | 85.5 ± 0.3 | 76.3 ± 0.7 |
10 | 59.02 ± 1.3 | 94.5 ± 0.55 | 78.5 ± 1 | |
20 | 85 ± 0.72 | 99 ± 0.1 | 88 ± 0.5 | |
EC50 (µg/mL) | 5.433 | 0.9233 | 2.676 | |
SI | 27.866 | 163.977 | 56.57 | |
ADV | 5 | 51.5 ± 0.14 | 72.12 ± 1.3 | 71 ± 0.55 |
10 | 61.94 ± 0.07 | 85.22 ± 0.52 | 83.5 ± 2.1 | |
20 | 99.6 ± 0.89 | 99.7 ± 0.13 | 89.7 ± 0.8 | |
EC50 (µg/mL) | 4.415 | 0.3664 | 0.2605 | |
SI | 34.29 | 413.66 | 581.19 | |
Coxsackie virus | 5 | 47 ± 1.4 | 98.5 ± 1 | 91.5 ± 1.2 |
10 | 73.5 ± 0.7 | 99.2 ± 1.5 | 94 ± 0.5 | |
20 | 99 ± 2.1 | 99.7 ± 0.9 | 95.2 ± 1.1 | |
EC50 (µg/mL) | 4.872 | 0.005669 | 0.1558 | |
SI | 31.075 | 30,280 | 971.75 |